58619-56-0

Usage

Derivative of piperazine

1-Piperazineacetonitrile is a modified version of the piperazine molecule, which is a heterocyclic organic compound.

Contains a cyano group

The presence of a cyano group (CN) in the molecule contributes to its nitrile functionality.

Nitrile functionality

The cyano group gives 1-Piperazineacetonitrile the properties of a nitrile, which is a chemical group with a triple bond between carbon and nitrogen.

Intermediate in synthesis

This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, meaning it is a reactant in the production of these compounds.

Building block in organic synthesis

1-Piperazineacetonitrile is used as a building block for the production of various molecules in organic synthesis.

Potential pharmaceutical applications

Due to its role as a precursor in the synthesis of bioactive compounds, 1-Piperazineacetonitrile has potential applications in the pharmaceutical industry.

Upstream product

• 676341-78-9 1-benzyloxycarbonyl-4-cyanomethylpiperazine 
• 110-85-0 piperazine 
• 107-14-2 chloroacetonitrile 
• 590-17-0 cyanomethyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1398718-01-8 (R)-1-amino-N-(1-cyano-2-(4'-((4-(cyanomethyl)piperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1272246-56-6 PZ₁₀₅₁-1 
• 916140-65-3 2-[4-(3-diphenylaminopropyl)piperazin-1-yl]ethylamine 
• 916140-58-4 [4-(3-diphenylaminopropyl)piperazin-1-yl]acetonitrile 

Relevant academic research and scientific papers

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM

In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.

A chimeric ligand approach leading to potent antiprion active acridine derivatives: Design, synthesis, and biological investigations

Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC50 value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.

Process improvements for the preparation of kilo quantities of a series of isoindoline compounds

A series of isoindoline analogues with either an indazole (HMR 2934, HMR 2651) or benzisoxazole (HMR 2543) appendage were prepared for the proposed treatment of psychiatric disorders such as obsessive compulsive disorder and attention deficit disorder. The isoindoline compounds were prepared by reduction of the corresponding phthalimides with LiAlH4. One compound was not chiral, and the other two required an enantioselective synthesis. The key step for these optically active analogues involved the coupling by an SN2 process of either a piperazynyl intermediate or a piperdinyl intermediate with methyl 3-benzyloxy-2-trifluoromethansulfonatopropionate. The products for these two analogues had >98% ee. Process improvements led to the multi-kilogram syntheses of each of these compounds.

Facile preparation of 3-(1-piperazinyl)-1H-indazoles

Pre-clinical evaluation of a potential antipsychotic agent required a convenient synthesis of 3-(1-piperazinyl)-1H-indazole derivatives. Improvements of the original preparation provided a five-step sequence to an unsubstituted piperazine intermediate, with a 67% overall yield. All intermediates were isolated by filtration.